공고 • Apr 21
Asian Phytoceuticals Public Company Limited Approves Dividend for the Year 2025, Payable on May 13, 2026 Asian Phytoceuticals Public Company Limited at its Annual General Meeting held on April 20, 2026, approve to pay dividend of THB 54,600,000 from the net profit and retained earnings to the Company's shareholders at the rate of THB 0.091 per share for the year 2025. The dividend will be paid to shareholders that are entitled to receive dividends, whose name appeared in the Shareholders Register Book (Record Date), on April 29, 2026 and the date of dividend payment shall be on May 13, 2026. 공고 • Apr 19
Asian Phytoceuticals Public Company Limited Approves Dividend, Payable on May 9, 2022 Asian Phytoceuticals Public Company Limited announced that at the Annual General Shareholders held on April 18, 2022, the Meeting resolved by unanimous votes to approve to pay dividend ofTHB 74,040,000 from the net profit and retained earnings to the Company's shareholders at the rate of THB 0.1234 per share. The dividend will be paid to shareholders that are entitled to receive dividends, whose name appeared in the Shareholders Register Book (Record Date), on April 27, 2022 and the date of dividend payment shall be on May 9, 2022. 공고 • Mar 03
Asian Phytoceuticals Public Company Limited, Annual General Meeting, Apr 18, 2022 Asian Phytoceuticals Public Company Limited, Annual General Meeting, Apr 18, 2022, at 14:00 SE Asia Standard Time. Location: Ballroom 1, 3rd Floor, The Emerald Hotel, No. 99/1 Soi Niam Uthit Ratchadaphisak Rd., Din Daeng, Bangkok Thailand Agenda: To consider and certify the Minutes of the Annual General Meeting of Shareholders of 2021; to Acknowledge the Company's performances of the previous year; to consider and approve the Company's financial statements for the fiscal year ended December 31, 2021; to consider and approve the dividend payment for operating results of 2021; to consider and approve the election of directors to replace those who retire by rotation; to consider and approve the directors' remuneration of 2022; to consider and approve the appointment of auditors and determine the annual remuneration of 2022; and to consider other matters (if any). 공고 • Mar 01
Asian Phytoceuticals Public Company Limited Proposes Dividend for 2021, Payable on May 9, 2022 Asian Phytoceuticals Public Company Limited announced that it will propose dividend payment at the rate of THB 0.1234 per share for 2021, Totaling of THB 74,040,000. April 27, 2022 will be the record date for the shareholders to receive dividend. The dividend shall be paid on May 9, 2022. 공고 • May 16
Asian Phytoceuticals Public Company Limited Announces the Progress of Apco's Research and Development Asian Phytoceuticals Public Company Limited officially launched an ONLINE project to advise people with HIV/AIDS people on how to achieve functional cure. APCO's success in immunotherapy with edible plant extracts has helped people with HIV/AIDS, who either have already been taking antiretroviral drugs or who are not yet on antiretroviral therapy, achieve good health with undetectable HIV without using antiretroviral drugs, which can have damaging side effects on their health both in the short- and long-run. Some volunteers who have continuously received undetectable HIV test results for more than 24 months decided to stop receiving APCO immunotherapy for six months and their test results still could not detect any HIV. This has raised hopes that some of them may have achieved eradication cure. As a result, APCO researchers launched an ONLINE project to advise people with HIV on how to regain their quality of life on par with normal people. This project is run by Prof. Dr. Pichaet Wiriyachitra and Ms. Siriporn Wonghiranyingyot with support from a specialist medical doctor as advisor and a marketing consultancy agency to ensure that the project reaches the target group and is a success in effectively eradicating HIV for them. The researchers at APCO hope that this project will help alleviate the suffering of hundreds of thousands of infected persons in Thailand and return them to normal healthy life and will lead also to the use of APCO innovation to help those with the same problem in other countries. Medical scientists have detected HIV since 1983 but until now there is no cure while no vaccine is available to prevent its infection. APCO's innovative immunotherapy with edible plant extract is the world's first innovation that alleviates the plight of people living with HIV/AIDS. A joint project to test the use of immunotherapy with edible plant extracts to treat cancer patients in China. Recently APCO has received approval from the FDA to produce the T-gain formula as food in a sealed container for export to a partner in China to be repackaged for use by cancer patients in a project with 50-100 patients. Should the symptoms ease among a minimum of 1 in 3 of the patients, the partner in China will set up a company to launch a cancer treatment program across China under a signed agreement to have APCO produce an average of 1.3 tons per month of T-gain. When the use of the product goes up to 3 tons, there will be an exchange of APCO shares with those of the company that uses T-gain to treat cancer in China. Recently the T-gain product has been shipped for use in the test and the results are expected to come out soon. A project to manufacture anti-aging/age-reversal and longevity products The team of researchers at APCO has monitored people who used APCO's edible plant immunotherapy innovation and had the following observations: Those with cancer not only see their symptoms eased but also have better overall health. Those using the innovation to prevent infection from the virus during the present outbreak see good results as well as good health. Those using the innovation to fight HIV infection see excellent results with a much stronger health as well as a more radiant complexion. This has led the team to ponder whether APCO innovation has an impact on lengthening telomeres which are at the end of the chromosome, leading to anti-aging, age-reversal and a longer life span. APCO then tested this innovation among healthy consumers who were asked to take 4 capsules a day for the first 4 weeks and 6 capsules per day for the next 4 weeks, for a total of 8 weeks. found that the sugar levels and blood pressure of all of these consumers were controlled to be within the normal range and that APCO innovation achieved the result of an increase in telomere length in almost all of these consumers and the increase was more than that achieved by similar products currently in the market. The lengthening of telomeres does not only cause anti-aging, age-reversal and longevity, but also prevents severe symptoms among people infected with COVID virus and can also repair damaged lungs in recovered patients, as well as repair bone marrow disorders, disorders of the skin, liver, kidneys, heart, brain, eyesight, fibrosis, lungs and gastrointestinal tract, etc. APCO researchers have recently improved the efficacy of this formula and the company is in the process of manufacturing and marketing planning to make the product available as widely as possible soon among both young people who desire a product for age-reversal and anti-aging and the older generation who want a longevity product. 공고 • Feb 23
Asian Phytoceuticals Public Company Limited, Annual General Meeting, Apr 19, 2021 Asian Phytoceuticals Public Company Limited, Annual General Meeting, Apr 19, 2021, at 14:00 SE Asia Standard Time. Location: 89 AIA Capital Center Tower Fl.30, Ratchadaphisak Rd., Din Daeng Bangkok Thailand Agenda: To consider the certify the minute of AGM 2020; to acknowledge the overall performance of the business operations of the previous year; to consider and approve the financial statements of the Company for the fiscal year ended December 31, 2020; to consider and approve the dividend payment for the year 2020 business performance; to consider and approve the election of boards to replace the boards who retire by rotation; to consider and approve the directors' remuneration for the year 2021; to consider and approve the appointment of the Company's auditors and the determination of the auditors' remuneration of 2021; and to consider other matters (if any). 
